---
title: "OBiO Tech faced a reduction of 900,000 shares by shareholder Shanghai Tan Ying and its concerted parties"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230817162.md"
description: "According to the Zhitong Finance APP, OBiO Tech announced that the company received a \"Notice of Shareholding Reduction Reaching 1%\" from its shareholder Shanghai Tanying and its concerted actors. Shanghai Tanying and its concerted actors will cumulatively reduce their holdings of the company's shares by 900,000 shares from January 1, 2025, to March 5, 2025"
datetime: "2025-03-06T11:25:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230817162.md)
  - [en](https://longbridge.com/en/news/230817162.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230817162.md)
generator: "portal-rs"
---

# OBiO Tech faced a reduction of 900,000 shares by shareholder Shanghai Tan Ying and its concerted parties

According to the Zhitong Finance APP, OBiO Tech (688238.SH) announced that the shareholder Shanghai Tan Ying and its concerted parties sent a "Notice of Shareholding Reduction Reaching 1%" to the company. From January 1, 2025, to March 5, 2025, Shanghai Tan Ying and its concerted parties cumulatively reduced their holdings by 900,000 shares

### Related Stocks

- [688238.CN](https://longbridge.com/en/quote/688238.CN.md)

## Related News & Research

- [REG - Shuka Minerals PLC - Further re Subscription](https://longbridge.com/en/news/297867499.md)
- [Khan demands Burnham block Heathrow expansion over net zero](https://longbridge.com/en/news/297836820.md)
- [BQE Water Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next](https://longbridge.com/en/news/297432071.md)
- [Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test](https://longbridge.com/en/news/297848437.md)
- [09:11 ETBioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline](https://longbridge.com/en/news/297657999.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**